These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10618553)

  • 21. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.
    Sharpe S; Fooks A; Lee J; Hayes K; Clegg C; Cranage M
    Virology; 2002 Feb; 293(2):210-6. PubMed ID: 11886240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope.
    Shams H; Poblete F; Rüssmann H; Galán JE; Donis RO
    Vaccine; 2001 Nov; 20(3-4):577-85. PubMed ID: 11672924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
    Evans DT; Chen LM; Gillis J; Lin KC; Harty B; Mazzara GP; Donis RO; Mansfield KG; Lifson JD; Desrosiers RC; Galán JE; Johnson RP
    J Virol; 2003 Feb; 77(4):2400-9. PubMed ID: 12551977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection of the same major T cell determinants of influenza nucleoprotein after vaccination or exposure to infectious virus.
    Brett SJ; Gao XM; Liew FY; Tite JP
    J Immunol; 1991 Sep; 147(5):1647-52. PubMed ID: 1715366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of epitopes by the Salmonella type III secretion system for vaccine development.
    Rüssmann H; Shams H; Poblete F; Fu Y; Galán JE; Donis RO
    Science; 1998 Jul; 281(5376):565-8. PubMed ID: 9677200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
    Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
    Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
    J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
    Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunogenic and protective characteristics of recombinant Lassa virus NP protein].
    Ignat'ev GM
    Vopr Virusol; 2002; 47(2):28-31. PubMed ID: 12046464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunogenicity of S1 gene DNA vaccine of mouse hepatitis virus delivered by attenuated Salmonella typhimurium].
    Jiao HM; Jiao XA; Yin YL; Pan ZM; Meng SS; Wang Y; Jiang JJ
    Wei Sheng Wu Xue Bao; 2007 Feb; 47(1):131-5. PubMed ID: 17436639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies.
    Hufert FT; Lüdke W; Schmitz H
    Arch Virol; 1989; 106(3-4):201-12. PubMed ID: 2476109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus.
    Morrison HG; Goldsmith CS; Regnery HL; Auperin DD
    Virus Res; 1991 Mar; 18(2-3):231-41. PubMed ID: 2042398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
    Lukashevich IS; Patterson J; Carrion R; Moshkoff D; Ticer A; Zapata J; Brasky K; Geiger R; Hubbard GB; Bryant J; Salvato MS
    J Virol; 2005 Nov; 79(22):13934-42. PubMed ID: 16254329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins.
    Kyburz D; Speiser DE; Battegay M; Hengartner H; Zinkernagel RM
    Eur J Immunol; 1993 Jul; 23(7):1540-5. PubMed ID: 8325330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization.
    Schödel F; Kelly S; Tinge S; Hopkins S; Peterson D; Milich D; Curtiss R
    Adv Exp Med Biol; 1996; 397():15-21. PubMed ID: 8718577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The localization and preliminary characteristics of antigenic sites (B epitopes) in the nucleocapsid protein of the Lassa virus].
    Vladyko AS; Bystrova SI; Malakhova IV; Kunitskaia LIa; Lemeshko NN; Kras'ko AG; Kozhich AT; Lukashevich IS
    Vopr Virusol; 1993; 38(1):30-4. PubMed ID: 7521097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.
    Berglund P; Fleeton MN; Smerdou C; Liljeström P
    Vaccine; 1999 Feb; 17(5):497-507. PubMed ID: 10073729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.